PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular... ( First Registration Study of an Inve...)

HOME >> MEDICINE >> TECHNOLOGY

PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy

Date:4/23/2008

First Registration Study of an Investigational Drug for Duchenne/Becker

Muscular Dystrophy

SOUTH PLAINFIELD, N.J., April 23 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), today announced the initiation of an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation. The primary objective of this registration-directed Phase 2b trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"DMD/BMD is a disorder with a significant need for better treatment options, and we are very encouraged by the promising results we have seen to date with PTC124," said Brenda Wong, M.D., Associate Professor of Pediatrics and Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, who was involved in the Phase 2a study and is one of the trial's lead investigators. "We believe that the safety profile of PTC124 and activity we have seen in the Phase 2a studies clearly support the initiation of this longer-term, registration-directed efficacy and safety study. We are very pleased to be a part of this groundbreaking trial."

Patients with DMD and BMD are boys and young men who lack dystrophin, a protein that is critical to the structural stability of muscle fibers. Patients develop progressive muscle weakness that leads to loss of ambulation, wheelchair dependency, and eventual decline in respiratory and cardiac function. It is estimated that one in 10 DMD patients are likely to have a Becker presentation, a milder form of the disease that is associated with later manifestation of symptoms. In essence, DMD and BMD represent a continuum of the same disease.

PTC124 is a novel, orally delivered drug in development f
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
2. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor

Post Your Comments:

(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...

(Date:5/22/2013)... May 22, 2013 Healthcare providers are ... content management (ECM) solution, for a ... System . These organizations identified enterprise content ... will use OnBase to optimize their Meditech ... (Logo: http://photos.prnewswire.com/prnh/20090130/65710LOGO ) ...

(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...

Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2 Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3 Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4 Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2 Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3 Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2 Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3

[0] Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine [0] Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System [0] Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer

... , NEW YORK, Dec. 8 ... already $232 billion, and it is projected to grow 11 percent annually, ... entitled The Science of Personalized Medicine: Translating the Promise into Practice ... personal and genetic variation , is creating a booming market, but ...

... , INDIANAPOLIS, Dec. 7 Roche Diagnostics ... center in Pleasanton, California, as part of an initiative to ... and independent laboratories on the west and east coasts. Roche ... and is planning to open an additional facility in New ...

Cached Medicine Technology:$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2 $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3 $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4 $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5 $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6 Roche Diagnostics Opens State-of-the-Art Training Center in California 2

$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers Roche Diagnostics Opens State-of-the-Art Training Center in California

(Date:5/22/2013)... May 22, 2013 DePuy Pinnacle ... DePuy Pinnacle Hip Replacement System continue to move forward ... Bernstein Liebhard LLP reports. According to an Order ... to produce monitoring reports associated with a 2007 criminal ... device marketing practices. Plaintiffs maintained in their ...

(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...

(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...

(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...

Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2 Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3 Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2 Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3 Health News:Hospitals profit when patients develop bloodstream infections 2 Health News:Hospitals profit when patients develop bloodstream infections 3 Health News:Hospitals profit when patients develop bloodstream infections 4 Health News:How To "Make Your Own Healthy Energy Bars" 2 Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2

[0] DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation [0] Zane Benefits Publishes New Information on Alabama Health Insurance Exchange [0] Hospitals profit when patients develop bloodstream infections [0] How To "Make Your Own Healthy Energy Bars"[0] Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats

... Feb. 20 /Xinhua-PRNewswire/ -- Venture Global Limited,unveils the ... pollution. With VEGO Power Blocker, cellphone users could ... Be Protected, VEGO Power Blocker Kills the Invisible ... VEGO Power Blocker is a piece of ultra-thinned ...

... first scientific evidence that deadly emerging diseases have ... the outbreaks main sources. They say new diseases ... the greatest threat to humans. Expansion of humans ... with wildlife are the reason, they say. Meanwhile, ...

... Anti-bleeding agent Trasylol tied to increased death, complications, studies ... new studies confirm an increased incidence of death and ... used to reduce bleeding during coronary artery bypass surgeries. ... over both the short- and long-term. , Trasylol,s German ...

... , , WEDNESDAY, Feb. 20 (HealthDay News) -- The time of day ... the difference between life and death. , Two new studies find ... weekends are more likely to die in the hospital than those ... acceptable, one researcher said. "We should not be treating patients ...

... heart disease had no ... risk factors, BALTIMORE, Feb. 20 In an effort to ... Foundation will,hold its annual Women,s Heart Health Fair on Tues., Feb. ... Mayor Sheila,Dixon has granted non-essential female workers two hours leave that ...

... put an end to toothaches, PHILADELPHIA, Feb. ... model, based in Philadelphia, announced that it is,expanding ... offering licensing,opportunities to qualifying dental practices, worldwide. This ... in advancing,affordable dental/health care available everywhere, to all., ...

Cached Medicine News:Health News:Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named 'VEGO Power Blocker' 2 Health News:Scientists make first map of emerging-disease hotpsots 2 Health News:Scientists make first map of emerging-disease hotpsots 3 Health News:More Evidence of Danger From Heart Surgery Drug 2 Health News:More Evidence of Danger From Heart Surgery Drug 3 Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 2 Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 3 Health News:Free Health Screenings Aim to Identify Risk of Heart Disease in Women 2 Health News:Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program 2

Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named 'VEGO Power Blocker'Scientists make first map of emerging-disease hotpsots More Evidence of Danger From Heart Surgery Drug In-Hospital Stroke Deaths Rise on Nights, Weekends Free Health Screenings Aim to Identify Risk of Heart Disease in Women Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program

Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....

For use with catalog #0540....

Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....

Antigenic Free Protein S, ELISA Method...

Medicine Products:

FS TEST UNIT FDP PLASMA LATEX STA LIATEST D-DI ASSERACHROM FREE PROTEIN S